Key facts
- It has raised $8.0M; the latest was Seed Round ($8.0M) in Jan 2025.
- Notable investors include 10D, AION Labs, Ahren Innovation Capital, Amiti Ventures, AstraZeneca — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Cassidy Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Cassidy Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cassidy Bio
Developer of a programmable platform designed for gene editing. The company's genomic foundation model reduces trial-and-error time of predictive, therapeutic-grade gene editing design by shortlisting the best candidates across gRNA design, enzyme selection, and genomic variation, enabling healthcare research industries to reduce research and development duration.
- Sector
- Healthcare
- HQ
- Tel Aviv, Israel
- Founded
- 2024
- Employees
- 23
- Website
- cassidy-bio.com/
- Ownership
- Privately Held (backing)
Cassidy Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cassidy Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cassidy Bio in its N-PORT filings yet. We sweep new filings monthly.